Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

on, which
is a counter-reaction of the body potentially decreasing the efficacy of current drug therapy1. In contrast to small molecule inhibitors, which display large variations in serum drug levels throughout the day, the vaccine-induced anti-angiotensin II antibodies were found to decline with a half-life of about 4 months. This may lead to a practically continuous inhibition of angiotensin II for weeks, which may in part account for the minor reactive rise observed in plasma renin concentration, and to the potent effect of the vaccine in early morning hours, as is further explained in the quote of Dr. Müller below.

A further important finding of the study is the dependence of efficacy on both the dose of the vaccine and the levels of induced anti-angiotensin II antibodies. Two doses of the vaccine, 100 ?g and 300 ?g, were tested in the trial. The induced anti-angiotensin antibody levels were significantly higher at the 300 ?g than at the 100 ?g dose (p=0.0098). Accordingly, blood pressure reduction was much larger and only significant at the 300 ?g dose (p=0.0498). Efficacy was thus driven by a longlasting, although reversible antibody response. Dr. Philipp Müller, EVP Clinical Development at Cytos Biotechnology comments on the study results:

“These data highlight a very important new aspect of the vaccine CYT006-AngQb, namely its exceptionally good control of the early morning blood pressure. So far, inhibition of the reninangiotensin system has been studied clinically only with small molecule inhibitors, which all produce a daily pattern of peaks and troughs in drug levels. Here, a trough in drug levels coincides with a natural rise of the blood pressure in early morning hours. The combination of these effects may lead to insufficient control of the early morning blood pressure surge. An intervention with a different pharmacokinetic profile like the vaccine approach, which avoids daily peaks and troughs in drug l
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/31/2014)... July 31, 2014 Endo International plc (NASDAQ: ... quarter 2014 revenues of $719 million, an increase of ... $712 million. Endo reported net income of $21 million ... of $35 million in the second quarter of 2013.  ... net income for the three months ended June 30, 2014 ...
(Date:7/31/2014)... Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced that the Company will receive a ... Asahi Kasei Pharma Corporation (Asahi Kasei). The payment ... a regulatory application to the Japanese Pharmaceutical and ... (collagenase clostridium histolyticum) for the treatment of Dupuytren,s ...
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
(Date:7/31/2014)... THURSDAY, July 31, 2014 (HealthDay News) -- Recovery time ... cholesterol-lowering medications known as statins, according to a new ... drugs may affect the body,s inflammatory response, reducing the ... And that seemed to be particularly true among people ... become one of the most widely prescribed medications in ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... Certified Internet Marketing Company, has introduced a new ... quite affordable.     , Ethane Web Technologies has designed ... the expectations of clients and Java Development service ... has given the company a confidence to promise ...
(Date:7/31/2014)... a unique protein that has the unusual property of destroying ... therefore be continually recreated and is no stable protein. The ... of coagulated blood. If you get a blood clot, it ... accumulated in a blood vessel, and therefore PAI-1 is extremely ... for helping people with a blood clot or other blood ...
(Date:7/31/2014)... 2014 Healthinsurancefacts.org has released a ... insurance plans by comparing quotes. , In order ... should consider comparing quotes. They can do this by ... simple questionnaire. , Clients should do proper research ... health insurance policies, and each of them can be ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... will host its first-ever event in New York on ... Eventi Hotel in Manhattan. , Featuring keynotes by ... Assemblyman Steve Katz (R-Yorktown), the event will include lunch ... Compassionate Care Act and the work NCIA is doing ...
Breaking Medicine News(10 mins):Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2Health News:Breakthrough in understanding of important blood protein 2Health News:Breakthrough in understanding of important blood protein 3Health News:Comparing Health Insurance Quotes Can Help Clients Find Affordable Plans 2Health News:THURSDAY, AUG 7: First-Ever National Cannabis Industry Association Event in New York Will Feature Senator Savino, Assemblyman Katz, & Industry Leaders 2
... however , MONDAY, Nov. 9 (HealthDay News) -- After a ... of cancer recurrence in the affected breast, a new study ... increased risk of developing breast cancer, and experts have suspected ... increased risk of cancer recurrence at the site of the ...
... Nov. 9 Abt Associates continues to ... consulting and support services with three recently awarded contracts ... Agency,s (FEMA) Office of Regional Operations, the National Commission ... Transit Authority (WMATA). The value of the combined ...
... WASHINGTON, Nov. 9 The American Academy of Physician ... assistants (PAs) practicing in the United States, applauds the ... care reform bill, H.R. 3962, the Affordable Health Care ... this reform bill will ultimately lower the cost of ...
... release is available in French . Montreal, November 9, ... female. In human bodies trillions of cells are coupled, too, and ... these don,t come in twos, they are regrouped into indistinguishable clusters. ... and illness scientists have long searched for ways to splice ...
... the world suffer from cataracts. Thomas Kohnen of the ... surgery with the implantation of an artificial lens in ... ( Dtsch Arztebl Int 2009; 106[43]: 695�). ... In Germany alone, more than 600,000 cataract operations are ...
... reason why African Americans are not receiving kidney/pancreas transplants ... racial groups. Dr. Keith Melancon, director of kidney ... professor of surgery at Georgetown University Medical Center, and ... the American Journal of Transplantation . ...
Cached Medicine News:Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 2Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2Health News:Physician bias might keep life-saving transplants from black and Hispanic patients 2
... True/Flex technology which has revolutionized the treatment ... unique fluted titanium construct was used in ... The biology of the tibia, with its ... presents special challenges to the healing process. ...
... 3080/3085 SP Bariatric Foot Extension provides extraordinary ... surgical capabilities for Amsco 3080 and 3085 ... Extension is rated for patients up to ... and easy attachment and full positioning capability. ...
... care you can provide to your patients, ... including innovative products, standardization and reimbursement guidelines, ... lavage systems deliver the performance needed for ... and foreign material. Each provides controlled pressure ...
... Pulsavac Wound Debridement System ... for pulsatile irrigation,and debridement. ... range of fluid pressure ... lavage to a penetrating ...
Medicine Products: